Drugs / SHR-4712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06993116 | Jun 2025 → May 2027 expected | neoplasm | Guangdong Hengrui Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06993116 ↗ |